Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Neoadjuvant Enzalutamide Prior to Prostatectomy.
Open access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review.Cancer medicine · 2026Pooled it
- Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials.Prostate cancer and prostatic diseases · 2024Pooled it
- Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.World journal of urology · 2021Pooled it
- Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.Journal for immunotherapy of cancer · 2026Trial
- Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial.World journal of urology · 2025Trial
- Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.The Journal of urology · 2021Trial
- Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Cardiometabolic health's influence on the efficacy of pre-operative hormone therapy for men with localized high-risk prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study.Annals of surgical oncology · 2026Article
- Recovery of urinary continence after neoadjuvant hormonal therapy plus radical prostatectomy: A multicenter retro-prospective cohort study with propensity score matching.Asian journal of urology · 2026Article
- Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis.International urology and nephrology · 2026Article
- The feasibility of [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Article
- Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer.Molecular cancer therapeutics · 2026Article
- Neoadjuvant androgen deprivation therapy with bicalutamide compared to hormonal agents in treating high-risk prostate cancer: a real-world cohort study.Translational cancer research · 2026Article
- Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial.The Prostate · 2026Article
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- Quantitative Morphometric Response to Neoadjuvant Androgen-Deprivation Therapy and Its Prognostic Role After Radical Prostatectomy.Research and reports in urology · 2026Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 2 countries.
Bruce MontgomeryDepartment of Medicine, University of Washington, Seattle, Washington. rbmontgo@uw.edu.
Maria S TretiakovaDepartment of Pathology, University of Washington, Seattle, Washington.
Anthony M JoshuaPrincess Margaret Cancer Centre, Toronto, Canada.
Martin E GleaveDepartment of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Neil FleshnerPrincess Margaret Cancer Centre, Toronto, Canada.
Glenn J BubleyBeth Israel Deaconess Medical Center, Boston, Massachusetts.
Elahe A MostaghelDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Kim N ChiBC Cancer Agency and University of British Columbia, Vancouver, Canada.
Daniel W LinDepartment of Urology, University of Washington, Seattle, Washington.
Martin SandaDepartment of Urology, Emory University, Atlanta, Georgia.
William NovotnyMedivation, Inc., San Francisco, California.
Kenneth WuMedivation, Inc., San Francisco, California.
Philip W KantoffDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Brett T MarckGeriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, and Department of Medicine, Division of Gerontology & Geriatric Medicine, University of Washington, Seattle, Washington.
Stephen PlymateGeriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, and Department of Medicine, Division of Gerontology & Geriatric Medicine, University of Washington, Seattle, Washington.
Steven P BalkBeth Israel Deaconess Medical Center, Boston, Massachusetts.
Peter S NelsonDepartment of Medicine, University of Washington, Seattle, Washington.
Alvin M MatsumotoDepartment of Medicine, University of Washington, Seattle, Washington.
Rosina T LisDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Adam KibelBrigham and Women's Hospital, Boston, Massachusetts.
Gabriel P HaasAstellas Pharma, Inc., Northbrook, Illinois.
Andrew KrivoshikAstellas Pharma, Inc., Northbrook, Illinois.
Alison HannahMedivation, Inc., San Francisco, California.
Mary-Ellen TaplinDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
University of Washington · USBeth Israel Deaconess Medical Center · USPrincess Margaret Cancer Centre · CAMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1MTumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI LODA, MASSIMO · 2002 to 2017
$36.2MSteroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Steven P. Balk · 2013 to 2026
$25.0MTransmembrane Proteases and Prostate CarcinogenesisP01CA085859 · NCI · UNIVERSITY OF WASHINGTON · PI VESSELLA, ROBERT LOUIS · 2002 to 2013
$21.2MTargeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate CancerI01BX003324 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2016 to 2024
–BLRD VA I01 BX003324NCI NIH HHS P01 CA085859NCI NIH HHS P01 CA163227NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA090381NCI NIH HHS P50 CA097186
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCombined Modality TherapyDutasterideHumansLeuprolideMaleMiddle AgedNeoadjuvant TherapyNeoplasm, ResidualNitrilesPhenylthiohydantoinProstatectomyProstate-Specific AntigenProstatic NeoplasmsBenzamidesDutasterideenzalutamideLeuprolideNitrilesPhenylthiohydantoinProstate-Specific AntigenReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.